The graft-versus-tumor effect in pediatric malignancy

Pediatric Clinics of North America

Volumn 57, Issue 1, 2010, Pages 67-81

  Fry, Terry J ^a   Willasch, Andre ^b   Bader, Peter ^b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Graft versus host disease; Graft versus host reaction; Graft versus leukemia; Graft versus tumor effect

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CHILDHOOD CANCER; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; MORBIDITY; NATURAL KILLER CELL; PROGNOSIS; REVIEW; SOLID TUMOR; T LYMPHOCYTE;

CHILD; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASMS; PROGNOSIS;

EID: 77951042806     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2009.12.002     Document Type: Review

References (102)

1. Barnes D.W., Corp M.J., Loutit J.F., et al. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J 1956, 2:626-627.
2. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979, 300:1068-1073.
3. Weiden P.L., Flournoy N., Sanders J.E., et al. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc 1981, 13:248-251.
4. Goldman J.M., Gale R.P., Horowitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806-814.
5. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991, 78:2120-2130.
6. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
7. Ringden O., Zwaan F., Hermans J., et al. European experience of bone marrow transplantation for leukemia. Transplant Proc 1987, 19:2600-2604.
8. Bacigalupo A., Van Lint M.T., Occhini D., et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991, 77:1423-1428.
9. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
10. Collins R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444.
11. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995, 86:2041-2050.
12. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
13. Ringden O., Karlsson H., Olsson R., et al. The allogeneic graft-versus-cancer effect. Br J Haematol 2009, 147(5):614-633.
14. Barrett A.J. Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol 2008, 142:877-888.
15. Collins R.H., Goldstein S., Giralt S., et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000, 26:511-516.
16. Porter D.L., Collins R.H., Hardy C., et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000, 95:1214-1221.
17. Shiobara S., Nakao S., Ueda M., et al. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: indications and dose escalation. Ther Apher 2001, 5:40-45.
18. Mackinnon S., Papadopoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995, 86:1261-1268.
19. Appelbaum F.R. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). Leukemia 1997, 11(Suppl 4):S15-S17.
20. Atra A., Millar B., Shepherd V., et al. Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation. Br J Haematol 1997, 97:165-168.
21. Kanamori H., Sasaki S., Yamazaki E., et al. Eradication of minimal residual disease during graft-versus-host reaction induced by abrupt discontinuation of immunosuppression following bone marrow transplantation in a patient with Ph1-ALL. Transpl Int 1997, 10:328-330.
22. Rymes N.L., Murray J.A., Holmes J.A. Abrupt cessation of immunosuppression in a patient with persistent acute lymphoblastic leukaemia following allogeneic transplantation. Clin Lab Haematol 1996, 18:45-46.
23. Grigg A., Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant 2004, 10:579-590.
24. Gross T.G., Hale G.A., He W., et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2009, [Epub ahead of print].
25. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000, 343:750-758.
26. Demirer T., Barkholt L., Blaise D., et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol 2008, 5:256-267.
27. Srinivasan R., Barrett J., Childs R. Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers. Semin Oncol 2004, 31:47-55.
28. Capitini C.M., Derdak J., Hughes M.S., et al. Unusual sites of extraskeletal metastases of Ewing sarcoma after allogeneic hematopoietic stem cell transplantation. J Pediatr Hematol Oncol 2009, 31:142-144.
29. Hosono A., Makimoto A., Kawai A., et al. Segregated graft-versus-tumor effect between CNS and non-CNS lesions of Ewing's sarcoma family of tumors. Bone Marrow Transplant 2008, 41:1067-1068.
30. Lucas K.G., Schwartz C., Kaplan J. Allogeneic stem cell transplantation in a patient with relapsed Ewing sarcoma. Pediatr Blood Cancer 2008, 51:142-144.
31. Lang P., Pfeiffer M., Muller I., et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr 2006, 218:321-326.
32. Inaba H., Handgretinger R., Furman W., et al. Allogeneic graft-versus-hepatoblastoma effect. Pediatr Blood Cancer 2006, 46:501-505.
33. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836-848.
34. Gattinoni L., Powell D.J., Rosenberg S.A., et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006, 6:383-393.
35. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
36. Goulmy E. Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Hum Immunol 2006, 67:433-438.
37. Vago L., Perna S.K., Zanussi M., et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009, 361:478-488.
38. Kawase T., Matsuo K., Kashiwase K., et al. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 2009, 113:2851-2858.
39. Gratwohl A., Hermans J., Apperley J., et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood 1995, 86:813-818.
40. Or R., Ackerstein A., Nagler A., et al. Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation. J Immunother 1998, 21:447-453.
41. Ringden O., Labopin M., Gluckman E., et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1996, 18:921-929.
42. Ringden O., Labopin M., Gorin N.C., et al. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?. Br J Haematol 2000, 111:1130-1137.
43. Mutis T. Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation. Int J Hematol 2003, 78:208-212.
44. Rezvani K., Barrett A.J. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol 2008, 21:437-453.
45. Kapp M., Stevanovic S., Fick K., et al. CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplant 2009, 43:399-410.
46. Wu C.J., Yang X.F., McLaughlin S., et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000, 106:705-714.
47. Yang X.F., Wu C.J., Chen L., et al. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res 2002, 62:5517-5522.
48. Hishizawa M., Imada K., Sakai T., et al. Antibody responses associated with the graft-versus-leukemia effect in adult T-cell leukemia. Int J Hematol 2006, 83:351-355.
49. Hishizawa M., Imada K., Sakai T., et al. Serological identification of adult T-cell leukaemia-associated antigens. Br J Haematol 2005, 130:382-390.
50. Hishizawa M., Imada K., Sakai T., et al. Identification of APOBEC3B as a potential target for the graft-versus-lymphoma effect by SEREX in a patient with mantle cell lymphoma. Br J Haematol 2005, 130:418-421.
51. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105:2973-2978.
52. Zitvogel L., Apetoh L., Ghiringhelli F., et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008, 8:59-73.
53. Ferrara J.L., Cooke K.R., Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol 2003, 78:181-187.
54. Delisle J.S., Gaboury L., Belanger M.P., et al. Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-gamma receptor-deficient hosts. Blood 2008, 112:2111-2119.
55. Capitini C.M., Herby S., Milliron M., et al. Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect. Blood 2009, 113:5002-5009.
56. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
57. Velardi A., Ruggeri L., Mancusi A., et al. Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation. Semin Immunopathol 2008, 30:489-503.
58. Leung W., Iyengar R., Turner V., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004, 172:644-650.
59. Lowe E.J., Turner V., Handgretinger R., et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 2003, 123:323-326.
60. Imamura M., Hashino S., Tanaka J. Graft-versus-leukemia effect and its clinical implications. Leuk Lymphoma 1996, 23:477-492.
61. Mehta J., Powles R., Kulkarni S., et al. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. Bone Marrow Transplant 1997, 20:129-135.
62. Porter D.L., Roth M.S., Lee S.J., et al. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996, 18:975-980.
63. Porter D.L., Connors J.M., Van Deerlin V.M., et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol 1999, 17:1234.
64. Bertz H., Burger J.A., Kunzmann R., et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997, 11:281-283.
65. Verdonck L.F., Lokhorst H.M., Dekker A.W., et al. Graft-versus-myeloma effect in two cases. Lancet 1996, 347:800-801.
66. Sosman J.A., Sondel P.M. The graft-vs-leukemia effect. Implications for post-marrow transplant antileukemia treatment. Am J Pediatr Hematol Oncol 1993, 15:185-195.
67. Collins R.H., Rogers Z.R., Bennett M., et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992, 10:391-395.
68. Abraham R., Szer J., Bardy P., et al. Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants. Bone Marrow Transplant 1997, 20:773-777.
69. Mehta J., Powles R., Singhal S., et al. Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995, 16:133-137.
70. Slavin S., Naparstek E., Nagler A., et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996, 87:2195-2204.
71. Mehta J., Powles R., Treleaven J., et al. Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy. Bone Marrow Transplant 1997, 19:709-719.
72. Gardiner N., Lawler M., O'Riordan J.M., et al. Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia. Bone Marrow Transplant 1998, 21:711-719.
73. Mackinnon S., Papadopoulos E.B., Carabasi M.H., et al. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: Is T cell dose important in determining biological response?. Bone Marrow Transplant 1995, 15:591-594.
74. Bacigalupo A., Soracco M., Vassallo F., et al. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997, 19:927-932.
75. Pati A.R., Godder K., Lamb L., et al. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 1995, 15:979-981.
76. Johnson B.D., Truitt R.L. Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1995, 85:3302-3312.
77. van Rhee F., Lin F., Cullis J.O., et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994, 83:3377-3383.
78. Guimond M., Busque L., Baron C., et al. Relapse after bone marrow transplantation: evidence for distinct immunological mechanisms between adult and paediatric populations. Br J Haematol 2000, 109:130-137.
79. Barrios M., Jimenez-Velasco A., Roman-Gomez J., et al. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia. Haematologica 2003, 88:801-810.
80. Formankova R., Sedlacek P., Krskova L., et al. Chimerism-directed adoptive immunotherapy in prevention and treatment of post-transplant relapse of leukemia in childhood. Haematologica 2003, 88:117-118.
81. Gorczynska E., Turkiewicz D., Toporski J., et al. Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: a report of 14 children. Bone Marrow Transplant 2004, 33:211-217.
82. Bader P., Niethammer D., Willasch A., et al. How and when should we monitor chimerism after allogeneic stem cell transplantation?. Bone Marrow Transplant 2005, 35:107-119.
83. Bader P., Kreyenberg H., Hoelle W., et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?. J Clin Oncol 2004, 22:1696-1705.
84. Passweg J.R., Tiberghien P., Cahn J.Y., et al. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant 1998, 21:153-158.
85. Bader P., Stoll K., Huber S., et al. Characterization of lineage-specific chimaerism in patients with acute leukaemia and myelodysplastic syndrome after allogeneic stem cell transplantation before and after relapse. Br J Haematol 2000, 108:761-768.
86. Sykes M., Sachs D.H. Bone marrow transplantation as a means of inducing tolerance. Semin Immunol 1990, 2:401-417.
87. Nikolic B., Sykes M. Bone marrow chimerism and transplantation tolerance. Curr Opin Immunol. 1997, 9:634-640.
88. Roux E., Abdi K., Speiser D., et al. Characterization of mixed chimerism in patients with chronic myeloid leukemia transplanted with T-cell-depleted bone marrow: involvement of different hematologic lineages before and after relapse. Blood 1993, 81:243-248.
89. Roux E., Helg C., Chapius B., et al. Mixed chimerism after bone marrow transplantation and the risk of relapse. Blood 1994, 84:4385-4386.
90. Locatelli F., Zecca M., Rondelli R., et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000, 95:1572-1579.
91. Kolb H.J. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang 1998, 74(Suppl 2):321-329.
92. Kolb H.J., Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 1997, 9:139-145.
93. Riddell S.R., Murata M., Bryant S., et al. T-cell therapy of leukemia. Cancer Control 2002, 9:114-122.
94. Luznik L., Fuchs E.J. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002, 9:123-137.
95. Bader P., Beck J., Schlegel P.G., et al. Additional immunotherapy on the basis of increasing mixed hematopoietic chimerism after allogeneic BMT in children with acute leukemia: is there an option to prevent relapse?. Bone Marrow Transplant 1997, 20:79-81.
96. Pulsipher M.A., Bader P., Klingebiel T., et al. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant 2009, 15:62-71.
97. Knechtli C.J., Goulden N.J., Hancock J.P., et al. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 1998, 102:860-871.
98. Sanchez J., Serrano J., Gomez P., et al. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol 2002, 116:686-694.
99. Spinelli O., Peruta B., Tosi M., et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 2007, 92:612-618.
100. Perez-Simon J.A., Caballero D., Diez-Campelo M., et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002, 16:1423-1431.
101. Uzunel M., Jaksch M., Mattsson J., et al. Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. Br J Haematol 2003, 122:788-794.
102. Bader P., Kreyenberg H., Henze G., et al. Predictive value of MRD monitoring after allogeneic SCT in relapsed childhood acute lymphoblastic leukaemia: analysis of the ALL-REZ BFM Group. Bone Marrow Transplant 2009, 43:40.